While reinforcing the importance of treating all known risk factors that contribute to atherosclerotic cardiovascular disease, ASCVD, physicians also need to recognize and treat systemic inflammation in CV disease, according to this guest column author who addresses the importance of identifying and reducing residual inflammatory risk.

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and

January 23, 2024 — Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced that an independent 

January 23, 2024 — Focused on delivering the latest scientific advancements and new treatments in cerebrovascular diseases and brain health science from around the world, this year's International Stroke Conference, ISC 2024, will be held Feb. 7-9 in Phoenix, Arizona.

January 22, 2024 — A physician-scientist from Massachusetts researching whether chemicals naturally occurring in foods could help treat heart disease, a genetics expert from Pennsylvania exploring the molecular mechanisms of lipid metabolism and cardiovascular diseases and a California-based professor of cardiovascular medicine studying how 

January 19, 2024 — Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now